Rigorous safety standards in Alliance trials
At the Alliance for Clinical Trials in Oncology, patient safety is at the foundation of clinical trials we design, open, and conduct. Evaluating new approaches to cancer treatment requires a careful balance of scientific innovation, rigorous oversight, and respect for the rights and well-being of every participant.
Participation in an Alliance clinical trial is always voluntary. Before enrolling, patients receive information about the clinical trial, including its purpose, potential benefits and risks, alternatives to participation, and their rights as research participants. The safety of participants is supported by a multilayered framework protect patients and maintain the integrity of our clinical trials.
Before a clinical trial can open to participants, its protocol undergoes scientific and operational review. Alliance disease and scientific committees bring together oncologists, researchers, statisticians, clinical research professionals, patient partners, and other experts to evaluate the scientific rationale, trial design, treatment approach, potential risk, and feasibility of the proposed research.
As part of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), Alliance studies also undergo the applicable NCI scientific and regulatory review processes before they can proceed. These reviews are designed to ensure that a trial addresses an important scientific question and that the potential risks to participants are appropriately considered and managed.
Alliance NCI-sponsored clinical trials generally rely on the NCI Central Institutional Review Board (CIRB) for centralized ethical review. The CIRB includes physicians, scientists, ethicists, and community representatives who review clinical trial protocols and informed consent materials with a focus on protecting the rights and welfare of research participants. Centralized IRB review helps promote consistent ethical standards across participating institutions while reducing duplication of local review.
The informed consent process is an essential part of this protection. Before joining a trial, patients receive information about the trial’s purpose, procedures, potential risks and benefits, alternatives to participation, and their rights. Patients have an opportunity to ask questions and decide whether participation is right for them.
Safety oversight continues throughout a clinical trial. Depending on the trial, safety may be monitored by the clinical trial study team, Alliance committees, NCI, and an independent data and safety monitoring board or other designated monitoring body. For trials overseen by the Alliance Data and Safety Monitoring Board (DSMB) the board reviews interim safety and outcome data prepared by the trial statistician and makes recommendations about whether a clinical trial should continue as planned, be modified, or be stopped.
If monitoring ever identifies an unexpected safety concern, the appropriate oversight bodies may recommend or require additional safeguards, changes to the trial, suspension of enrollment, or trial closure, as appropriate. In some circumstances, a clinical trial may also be stopped early because the results provide compelling evidence of benefit or because the trial question can no longer be answered as originally planned.
The Alliance Statistics and Data Management Center (SDMC) provides centralized statistical and data management support for Alliance clinical trials. Standardized systems and procedures help participating sites collect, report, and review clinical and safety information consistently. The SDMC works with clinical trial study teams and participating institutions to support data quality, protocol compliance, and timely reporting of adverse events and other important trial information. These processes allow study teams and oversight bodies to identify potential safety signals and evaluate emerging data throughout the course of a trial.
Alliance clinical trials are conducted through a broad network of academic medical centers, hospitals, and community oncology practices, including sites participating through the NCI Community Oncology Research Program (NCORP). Participating institutions must meet applicable regulatory, clinical, pharmacy, data-management, and research requirements before they can conduct Alliance trials. Site personnel receive trial-specific training and follow the protocol and applicable safety and reporting requirements. This network allows patients to participate in clinical research in a range of care settings while maintaining the scientific, ethical, and regulatory standards required for Alliance and NCI-sponsored research.
Patient safety is not the responsibility of any single committee, institution, or individual. It is built into every stage of clinical research—from the initial scientific concept and protocol development through informed consent, clinical trial conduct, data collection, safety monitoring, and analysis. Through this shared system of oversight, the Alliance works to ensure that advancing cancer research never loses sight of the people who make that research possible: the patients who choose to participate.